The latest financial statement is for the year ending 2025-12-27.
| Cash Flow | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 |
|---|---|---|---|---|
| Net income (loss) | -142,163 | 25,291 | 480,370 | 492,608 |
| Depreciation and amortization | 403,312 | 361,741 | 314,124 | 303,870 |
| Goodwill impairment | 165,000 | 215,000 | - | - |
| Long-lived asset impairments | 259,080 | 51,825 | 41,911 | - |
| Stock-based compensation | 71,083 | 69,891 | 72,048 | 73,617 |
| Loss on debt extinguishment and amortization of other financing costs | - | - | -3,967 | -4,118 |
| Deferred income taxes | -75,292 | -67,428 | -50,903 | -35,884 |
| Write down of inventories | 12,444 | 46,992 | - | - |
| Loss (gain) on venture capital and strategic equity investments, net | - | - | - | -26,775 |
| (gain) loss on venture capital and strategic equity investments, net | - | -12,910 | 97,827 | - |
| (gains) losses and impairments on venture capital and strategic equity investments, net | -24,911 | - | - | - |
| Provision for credit losses | 6,062 | 14,774 | 18,225 | 6,706 |
| (gain) loss on divestitures, net | 3,376 | -659 | -961 | 123,405 |
| Changes in fair value of contingent consideration arrangements | - | - | 1,810 | -3,753 |
| Other, net | -2,504 | -33,251 | -1,592 | -27,542 |
| Trade receivables and contract assets, net | -35,737 | -21,612 | 33,434 | 150,570 |
| Inventories | 48,777 | -16,804 | 62,301 | 78,523 |
| Accounts payable | 2,869 | -14,271 | -20,427 | -2,652 |
| Accrued compensation | 79,308 | -27,604 | 12,447 | -42,164 |
| Deferred revenue | -38,139 | 18,541 | -21,743 | 57,658 |
| Customer contract deposits | 14,652 | 6,584 | -15,564 | 30,457 |
| Other assets and liabilities, net | 31,569 | 51,995 | -38,642 | -33,240 |
| Net cash provided by operating activities | 737,646 | 734,577 | 683,898 | 619,640 |
| Capital expenditures | 219,152 | 232,967 | 318,528 | 324,733 |
| Purchases of investments and contributions to venture capital investments | 20,076 | 52,876 | 54,215 | 158,274 |
| Acquisition of businesses and assets, net of cash acquired | 0 | 5,479 | 194,785 | 283,392 |
| Proceeds from sale of investments | 9,102 | 41,687 | 6,667 | 4,549 |
| Proceeds from sale of businesses, net | 17,441 | - | - | 163,275 |
| Other, net | -3,364 | -4,549 | 2,294 | 9,347 |
| Net cash used in investing activities | -209,321 | -245,086 | -563,155 | -607,922 |
| Proceeds from long-term debt and revolving credit facility | 1,227,534 | 1,081,581 | 776,353 | 2,952,430 |
| Payments on long-term debt, revolving credit facility, and finance lease obligations | 1,349,317 | 1,493,769 | 851,676 | 2,932,636 |
| Proceeds from exercises of stock options | 714 | 23,878 | 25,597 | 25,110 |
| Purchase of treasury stock | 360,673 | 119,175 | 24,155 | 38,651 |
| Payment of debt extinguishment and financing costs | - | - | 0 | 0 |
| Payments of contingent consideration | 21,822 | 0 | 2,711 | 10,356 |
| Purchase of remaining equity interests of other redeemable noncontrolling interest | 19,140 | 12,000 | 4,784 | 30,533 |
| Other, net | -14,022 | -31,442 | -4,145 | -7,761 |
| Net cash used in financing activities | -536,726 | -550,927 | -85,521 | -42,397 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 18,828 | -17,474 | 8,044 | 25,579 |
| Net change in cash, cash equivalents, and restricted cash | 10,427 | -78,910 | 43,266 | -5,100 |
| Cash and cash equivalents at beginning of period | 205,570 | 284,480 | 241,214 | 246,314 |
| Cash and cash equivalents at end of period | 215,997 | 205,570 | 284,480 | 241,214 |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)